Ekkio Capital has made a final close for Ekkio Capital IV on €161m, surpassing its €150m target.
New and historical backers invest in Belgium-based Imcyse, a developer of immunotherapies
Buyout of the baking product company is the GP's fifth UK deal since opening a Manchester office
Sale ends an eight-year holding period for the GP, which owned an 83.4% stake in the company
Fresh capital will be used to develop BioSerenity's products beyond their initial focus